A new CRISPR/Cas9 therapy can suppress aging

Medical Xpress | February 19, 2019

Aging is a leading risk factor for a number of debilitating conditions, including heart disease, cancer, and Alzheimer's disease, to name a few. This makes the need for anti-aging therapies all the more urgent. Now, Salk Institute researchers have developed a new gene therapy to help decelerate the aging process. The findings, published on February 18, 2019, in the journal Nature Medicine, highlight a novel CRISPR/Cas9 genome-editing therapy that can suppress the accelerated aging observed in mice with Hutchinson-Gilford progeria syndrome, a rare genetic disorder that also afflicts humans. This treatment provides important insight into the molecular pathways involved in accelerated aging, as well as how to reduce toxic proteins via gene therapy. "Aging is a complex process in which cells start to lose their functionality, so it is critical for us to find effective ways to study the molecular drivers of aging," says Juan Carlos Izpisua Belmonte, a professor in Salk's Gene Expression Laboratory and senior author of the paper. "Progeria is an ideal aging model because it allows us to devise an intervention, refine it and test it again quickly."

Spotlight

Miami Stem Cell’s mission is to control orthopedic related pain and suffering by using the latest and most innovative Regenerative Medicine therapy procedures available today.

Spotlight

Miami Stem Cell’s mission is to control orthopedic related pain and suffering by using the latest and most innovative Regenerative Medicine therapy procedures available today.

Related News

CELL AND GENE THERAPY

Ultima Genomics and Olink collaborate to develop solution for high-throughput proteomics

Ultima Genomics | June 09, 2022

Olink Holding AB (publ) ("Olink") (Nasdaq: OLK) and Ultima Genomics ("Ultima") today announced that they have entered into a collaboration to enable the use of the Olink® Explore high-throughput proteomics platform with Ultima's sequencing architecture. Ultima Genomics and Olink are working towards a seamless pairing of the existing Olink® Explore assay and Ultima Genomics' sequencing system, and are collaborating with joint customers to enable larger-scale projects. The companies expect this will be accomplished by offering Ultima-specific library modules, along with an Olink-provided data analysis solution. Initial proof of concept data gathered by the companies shows similar performance to the existing Explore assay, signaling its potential for high-throughput proteomics customers. Additional information will be provided by Ultima during a panel discussion today, June 8, at the Advances in Genome Biology and Technology (AGBT) general meeting in Orlando, Florida. With the next-generation sequencing market expected to undergo a significant evolution in the months and years ahead, Olink is committed to enabling broad access to its unique and industry-leading Explore technology, As more labs embrace the promise of proteomics, we believe we are approaching an inflection point; and efforts such as our collaboration with Ultima will be a critical factor in developing the market and reaching as many customers as possible." Jon Heimer, CEO of Olink. This non-exclusive collaborative framework is a continuation of Olink's strategy it has executed in NGS since 2020 and combines the strengths of both companies' technologies. These efforts are in line with Olink's previously communicated operational planning and are intended to provide customers with options in choosing the sequencing platform that is optimal for their needs. About Olink Olink Holding AB (Nasdaq: OLK) is a company dedicated to accelerating proteomics together with the scientific community, across multiple disease areas to enable new discoveries and improve the lives of patients. Olink provides a platform of products and services which are deployed across major biopharmaceutical companies and leading clinical and academic institutions to deepen the understanding of real-time human biology and drive 21st-century healthcare through actionable and impactful science. The Company was founded in 2016 and is well established across Europe, North America, and Asia. Olink is headquartered in Uppsala, Sweden. About Ultima Genomics Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies. Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth, and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.

Read More

CELL AND GENE THERAPY

IndyGeneUS AI Secures Pathogen Sequencing for COVID-19 Genomic Surveillance Initiatives

IndyGeneUS AI | May 20, 2021

Through collaborations, IndyGeneUS AI has acquired genomic analysis and testing capabilities. This pathogen sequencing capacity has emerged at a critical moment in efforts to improve genomic surveillance and monitor COVID-19 variant strains across the continent. IndyGeneUS founder and CEO Yusuf Henriques emphasized the importance of this work. "COVID-19 and its variants pose a danger to the entire African continent, so we must act quickly. Our partners understand the urgency of this mission and are united with their cooperation." Next-generation sequencing (NGS)-based genotyping, targeted sequencing, and comprehensive bioinformatics analysis are among the capabilities. Comparative genomic analysis, disease genetics, epigenomics, and genome mapping are some of the applications of our capabilities. Bradford Wilson, Ph.D., Chief Scientific Officer at IndyGeneUS AI, said, "These capabilities are pivotal for the Continent and the future of precision medicine." "We are currently in talks with several large pharmaceutical firms that see the value of what we are developing to combat infectious and non-communicable diseases alike," he said. In less than a year, IndyGeneUS AI has partnered with Kenyan organizations such as the KAVI Institute of Clinical Research at the University of Nairobi and Afya Rekod. We've also teamed up with Encrypgen, which has created a blockchain-encrypted marketplace for commercializing insights gleaned from our repository and compensating participants who contribute data. IndyGeneUS has certainly understood the increasing need for infrastructure to sustain genomic surveillance activities by developing sequencing capabilities. Following the introduction of COVID-19 variant strains, the World Health Organization (WHO) and the African Centres for Disease Control (Africa CDC) established a network of laboratories last year to improve the continent's capacity to identify emerging variants of concern. More funding and infrastructure are needed for these initiatives. IndyGeneUS intends to accelerate sequencing capabilities across Africa by using public and private partnerships. About IndyGeneUS AI IndyGeneUS AI is a genomics company based in Nairobi is also developing the world's largest block-chain encrypted repository of African clinical and multi-omics data for disease prevention and diagnosis, drug discovery and development, clinical disease management, and the promotion of precision health equity. Mr. Yusuf Henriques, COO Dr. Wilmot Allen, and CSO Dr. Bradford Wilson formed IndyGeneUS. The company, which is owned by African Americans and Africans, has offices in Washington, DC, and a presence in South Africa through the Founder Institute. The Founder Institute is the world's largest pre-seed startup accelerator.

Read More

CELL AND GENE THERAPY

Taysha Gene Therapies Announces New Additions to Leadership Team to Deepen Manufacturing and Communications Capabilities

Taysha | December 30, 2020

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-driven gene therapy organization focused in on creating and commercializing AAV-based quality treatments for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today reported new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relations. Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy organization zeroed in on creating and commercializing AAV-based qgene therapies for the treatment of monogenic infections of the focal sensory system in both uncommon and huge patient populaces, today declared new increases to its authority group with the arrangements of Greg Gara as Senior Vice President of Manufacturing and Kimberly Lee, D.O., as Senior Vice President of Corporate Communications and Investor Relations.

Read More